Lassus A, Lauharanta J, Juvakoski T, Kanerva L
Dermatologica. 1983;166(4):215-9. doi: 10.1159/000249871.
A total of 40 patients with palmoplantar pustulosis (PPP) were initially treated with oral etretinate (Tigason) in an open trail with a maximum treatment period of 16 weeks. Remission, with only slight residual changes in some cases, was achieved in 26 patients (65%) who were randomized to either a low dose of Tigason or placebo. In the Tigason group, 7 of 11 patients were still in remission afer 6 months while in the placebo group, remission persisted in 4 of the 10 patients who stayed in the study throughout the whole 6 months' period. Alopecia led to stopping the treatment in 6 patients and desquamation of the healthy skin in 2 patients. Other side-effects were only mild. As a conclusion, Tigason shows a beneficial effect in the majority of patients with PPP and is better than placebo in preventing relapse of the disease but intolerable side-effects restrict its use in many patients.
共有40例掌跖脓疱病（PPP）患者在一项开放试验中接受口服阿维A酯（银屑灵）治疗，最长治疗期为16周。随机接受低剂量银屑灵或安慰剂治疗的26例患者（65%）实现了缓解，部分病例仅有轻微残留变化。在银屑灵组中，11例患者中有7例在6个月后仍处于缓解状态，而在安慰剂组中，在整个6个月研究期间持续参与研究的10例患者中有4例仍处于缓解状态。脱发导致6例患者停止治疗，2例患者出现健康皮肤脱屑。其他副作用仅为轻度。总之，银屑灵对大多数PPP患者显示出有益效果，在预防疾病复发方面优于安慰剂，但难以耐受的副作用限制了其在许多患者中的应用。
